An observational study in Pulmonary Fibrosis, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Active, not recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
The study aims to develop an innovative nano-platform for the treatment of lung fibrogenic disorders (LFD). The approach involves local delivery by inhalation of drug-loaded liposomes, coated with hyaluronic acid (HA) to directly target CD44+ pathogenic cells. We aim to expand and develop the formulation "XHALIP¿ (patent pending) by the following steps: 1) Characterization of safety and bioavailability in healthy and lung fibrogenic disorders (LFD) mice; 2) Evaluation of the pharmacokinetics and uptake by human LFD fibroblasts and macrophages and on healthy/LFD mice; 3) testing of antifibrotic/-inflammatory activities of the most promising XHALIP on mouse LFD models and translational studies on lung cells/tissues from LFD patients AIM 1: XHALIP characterization and bio-nano interaction AIM 2: Organ and cell lung Targeting AIM 3: Efficacy assessment in lung fibrosis models
680 studies on the registry are indexed under Pulmonary Fibrosis; 119 are open to participants now.
This study's planned enrollment of 30 is below the median of 130 across 229 observational studies indexed under Pulmonary Fibrosis.
Browse Pulmonary Fibrosis studies →Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 255 studies on the registry; 113 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients of the Rheumatology and Pneumology unit
Exclusion Criteria:
TEst in vitro ability of specific liposomes to deliver drugs to fibroblasts and macrophages from pulmonary fibrosis patients
liposome characterization and bio-nano interaction
Time frame: 12 months
Plan to share: No — A patent is pending for the liposomes in study
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Policlinico San Matteo di Pavia